MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
Simone Claudiani,
Aoife Gatenby,
Richard Szydlo,
George Nesr,
Adi Shacham Abulafia,
Renuka Palanicawandar,
Georgios Nteliopoulos,
Jamshid Khorashad,
Letizia Foroni,
Jane F. Apperley,
Dragana Milojkovic
Affiliations
Simone Claudiani
Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK;Centre for Haematology, Imperial College London, London, UK
Aoife Gatenby
Centre for Haematology, Imperial College London, London, UK
Richard Szydlo
Centre for Haematology, Imperial College London, London, UK
George Nesr
Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK;Centre for Haematology, Imperial College London, London, UK
Adi Shacham Abulafia
Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Centre, Petah-Tiqva, Israel
Renuka Palanicawandar
Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
Georgios Nteliopoulos
Centre for Haematology, Imperial College London, London, UK
Jamshid Khorashad
Centre for Haematology, Imperial College London, London, UK
Letizia Foroni
Centre for Haematology, Imperial College London, London, UK
Jane F. Apperley
Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK;Centre for Haematology, Imperial College London, London, UK
Dragana Milojkovic
Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
The majority of patients with newly diagnosed chronic myeloid leukemia (CML) will enjoy a life expectancy equivalent to that of unaffected individuals, but will remain on life-long treatment with a concomitant requirement for on-going hospital interactions for molecular monitoring and drug dispensing. In order to determine more accurately the frequency of monitoring required, we performed a ‘real-life’ retrospective single-center cohort study of 450 patients with CML in at least major molecular remission (MR3) to analyze the risk of loss of MR3 [defined as at least 2 consecutive real-time quantitative polymerase chain reaction (RT-qPCR) results >0.1% International Scale (IS)]. Patients who achieved sustained MR4 (sMR4, BCR-ABL1 RT-qPCR
